Genocea Gets UW, Hutch Patents

Genocea Biosciences, a Cambridge, MA-based vaccine developer, said today it has obtained licenses to 25 pending or issued patents on herpes simplex type 2 antigens from the University of Washington and Fred Hutchinson Cancer Research Center. Those antigens could be used as  the basis for a new immune-boosting treatment for genital herpes. Genocea CEO Staph Bakali described the company’s plans to treat herpes in an interview with Xconomy in December.

Trending on Xconomy